|
| Type of cancer | Function | References |
|
| PD-L1 in colorectal carcinoma (CRC) | The presence of PD-L1 is an independent predictor of CC prognosis. Proliferating, migrating, and invading cells can be prevented by B7-H1 knockdown. | [22] |
| PD-L1 in cervical cancer (CC) | PD-L1 has no considerable impact on the survival of patients with CC. | [23] |
| PD-L1 in pancreatic cancer (PC) | PD-L1 is a new prognostic factor for patients suffering from PC. | [24] |
| PD-L1 in BC | The PD-L1 expression is an independent negative prognostic factor in human BC. | [25] |
| PD-L1 in renal cell carcinoma (RCC) | Soluble PD-L1 has been determined in the sera of patients suffering from RCC and may systemically impair host immunity. Furthermore, the survival rate of RCC patients (with B7-H1 tumors) is very low. | [26, 27] |
| PD-L1 in non-small cell lung carcinoma (NSCLC) | In the case of surgically removed NSCLC, PD-L1 elevated expression was linked with the mutations in EGFR that independently predicted the survival outcomes for this carcinoma. | [28] |
| PD-L1 in ovarian cancer (OC) | PD-L1 expression on cancerous cells is an independent predictor of OC. | [29] |
| PD-L1 in malignant melanoma (MM) | Melanoma patients with an elevated expression of PD-L1 have a poorer survival rate. | [30] |
| PD-L1 in esophageal cancer (EC) | PD-L1 and PD-L2 could predict the survival outcomes of patients suffering from EC, paving the way for new immunotherapies that target the PD-1/PD-L cascade. | [31] |
| PD-L1 in nasopharyngeal carcinoma (NPC) | The co-expression of PD-1/PD-L1 revealed the tumor microenvironment’s selective suppression of cytotoxic lymphocytes and predicted NPC recurrence and development post conventional treatments. | [32] |
|
